174 related articles for article (PubMed ID: 32183159)
21. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression.
Mukherjee A; Soyal SM; Li J; Ying Y; He B; DeMayo FJ; Lydon JP
FASEB J; 2010 Nov; 24(11):4408-19. PubMed ID: 20605949
[TBL] [Abstract][Full Text] [Related]
22. Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells.
Obr AE; Grimm SL; Bishop KA; Pike JW; Lydon JP; Edwards DP
Mol Endocrinol; 2013 Nov; 27(11):1808-24. PubMed ID: 24014651
[TBL] [Abstract][Full Text] [Related]
23. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
[TBL] [Abstract][Full Text] [Related]
25. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.
Beleut M; Rajaram RD; Caikovski M; Ayyanan A; Germano D; Choi Y; Schneider P; Brisken C
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):2989-94. PubMed ID: 20133621
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
27. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
28. RANK expression as a prognostic and predictive marker in breast cancer.
Pfitzner BM; Branstetter D; Loibl S; Denkert C; Lederer B; Schmitt WD; Dombrowski F; Werner M; Rüdiger T; Dougall WC; von Minckwitz G
Breast Cancer Res Treat; 2014 Jun; 145(2):307-15. PubMed ID: 24737168
[TBL] [Abstract][Full Text] [Related]
29. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
[TBL] [Abstract][Full Text] [Related]
30. RANK/RANKL: regulators of immune responses and bone physiology.
Leibbrandt A; Penninger JM
Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
[TBL] [Abstract][Full Text] [Related]
31. Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.
Warren JT; Zou W; Decker CE; Rohatgi N; Nelson CA; Fremont DH; Teitelbaum SL
J Cell Biochem; 2015 Nov; 116(11):2476-83. PubMed ID: 25864714
[TBL] [Abstract][Full Text] [Related]
32. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
33. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
Beristain AG; Narala SR; Di Grappa MA; Khokha R
J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
[TBL] [Abstract][Full Text] [Related]
34. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
35. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
36. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
37. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
38. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
39. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
40. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
